Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients.

• Hoofdauteurs: Sophie Lachau-Durand (Auteur), Lieve Lammens (Auteur), Bas-Jan van der Leede (Auteur), Jacky Van Gompel (Auteur), Graham Bailey (Auteur), Marc Engelen (Auteur), Ann Lampo (Auteur)
• Formaat: Boek
• Gepubliceerd in: Public Library of Science (PLoS), 2019-01-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

<h4>Background</h4>Flubendazole, originally developed to treat infections with intestinal nematodes, has been shown to be efficacious in animal models of filarial infections. For treatment of filarial nematodes, systemic exposure is needed. For this purpose, an orally bioavailable amorph...